Vesiculobullous diseases in relation to lupus erythematosus

References

• Hejazi EZ, Werth VP. Cutaneous lupus erythematosus: an update on pathogenesis, diagnosis and treatment. Am J Clin Dermatol. 2016;17(2):135–146. doi:10.1007/s40257-016-0173-926872954
   PubMed Web of Science ®Google Scholar
• Pons-Estel GJ, Salerni GE, Serrano RM, et al. Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature. Autoimmun Rev. 2011;10(11):679–684. doi:10.1016/j.autrev.2011.04.02821569864
   PubMed Web of Science ®Google Scholar
• Contestable JJ, Edhegard KD, Meyerle JH. Bullous systemic lupus erythematosus: a review and update to diagnosis and treatment. Am J Clin Dermatol. 2014;15(6):517–524. doi:10.1007/s40257-014-0098-025358414
   PubMed Web of Science ®Google Scholar
• Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981;4(4):471–475. doi:10.1016/s0190-9622(81)80261-77229150
   PubMed Web of Science ®Google Scholar
• Sontheimer RD. The lexicon of cutaneous lupus erythematosus–a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus. 1997;6(2):84–95. doi:10.1177/0961203397006002039061656
   PubMed Web of Science ®Google Scholar
• Malik M, Ahmed AR. Concurrence of systemic lupus erythematosus and pemphigus: coincidence or correlation? Dermatology. 2007;214(3):231–239. doi:10.1159/00009958817377385
   PubMed Web of Science ®Google Scholar
• Sawamura S, Kajihara I, Makino K, et al. Systemic lupus erythematosus associated with myasthenia gravis, pemphigus foliaceus and chronic thyroiditis after thymectomy. Australas J Dermatol. 2017;58(3):e120–e122. doi:10.1111/ajd.1251027270472
   PubMed Web of Science ®Google Scholar
• Stoll DM, King LE Jr. Association of bullous pemphigoid with systemic lupus erythematosus. Arch Dermatol. 1984;120(3):362–366.6367666
   PubMedGoogle Scholar
• Kurano TL, Lum CA, Izumi AK. The association of dermatitis herpetiformis and systemic lupus erythematosus. J Am Acad Dermatol. 2010;63(5):892–895. doi:10.1016/j.jaad.2009.05.037.20739096
   PubMed Web of Science ®Google Scholar
• Malik M, Gurcan HM, Ahmed AR. Coexistence of mucous membrane pemphigoid and connective-tissue disease. Clin Exp Dermatol. 2010;35(2):156–159. doi:10.1111/j.1365-2230.2009.03222.x19438545
   PubMed Web of Science ®Google Scholar
• Marinovic B, Basta-Juzbasic A, Bukvic-Mokos Z, Leovic R, Loncaric D. Coexistence of pemphigus herpetiformis and systemic lupus erythematosus. J Eur Acad Dermatol Venereol. 2003;17(3):316–319.doi:10.1046/j.1468-3083.2003.00738.12702075
   PubMed Web of Science ®Google Scholar
• McHenry PM, Dagg JH, Tidman MJ, Lever RS. Epidermolysis bullosa acquisita occurring in association with systemic lupus erythematosus. Clin Exp Dermatol. 1993;18(4):378–380.doi:10.1111/j.1365-2230.1993.tb02224.x8403483
   PubMed Web of Science ®Google Scholar
• Tobon GJ, Toro CE, Bravo JC, Canas CA. Linear IgA bullous dermatosis associated with systemic lupus erythematosus: a case report. Clin Rheumatol. 2008;27(3):391–393. doi:10.1007/s10067-007-0752-517932615
   PubMed Web of Science ®Google Scholar
• Torchia D, Romanelli P, Kerdel FA. Erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis associated with lupus erythematosus. J Am Acad Dermatol. 2012;67(3):417–421. doi:10.1016/j.jaad.2011.10.01222101216
   PubMed Web of Science ®Google Scholar
• van Tuyll van Serooskerken AM, Habets JM, Badeloe S, Poblete-Gutierrez P, Frank J. Porphyria cutanea tarda in pre-existent lupus erythematosus–is there an association? Int J Dermatol. 2007;46(Suppl 3):S50–S52. doi:10.1111/j.1365-4632.2007.03515.x
   Google Scholar
• Ting W, MS S, Racila D, Scofield RH, Sontheimer RD. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus. 2004;13(12):941–950. doi:10.1191/0961203304lu2037sa15645750
   PubMed Web of Science ®Google Scholar
• Lee HY, Tey HL, Pang SM, Thirumoorthy T. Systemic lupus erythematosus presenting as Stevens-Johnson syndrome and toxic epidermal necrolysis: a report of three cases. Lupus. 2011;20(6):647–652. doi:10.1177/096120331038516221148602
   PubMed Web of Science ®Google Scholar
• Zeitouni NC, Funaro D, Cloutier RA, Gagne E, Claveau J. Redefining Rowell’s syndrome. Br J Dermatol. 2000;142(2):343–346. doi:10.1046/j.1365-2133.2000.03306.x10730772
   PubMed Web of Science ®Google Scholar
• Rowell NR, Beck JS, Anderson JR. Lupus erythematosus and erythema multiforme-like lesions. A syndrome with characterisctic immunological abnormalitities. Arch Dermatol. 1963;88(2):176–180. doi:10.1001/archderm.1963.0159020006401214043605
   PubMedGoogle Scholar
• Yildirim Cetin G, Sayar H, Ozkan F, Kurtulus S, Kesici F, Sayarlioglu M. A case of toxic epidermal necrolysis-like skin lesions with systemic lupus erythematosus and review of the literature. Lupus. 2013;22(8):839–846. doi:10.1177/096120331349224223761100
   PubMed Web of Science ®Google Scholar
• Duarte-Garcia A, Fang H, To CH, Magder LS, Petri M. Seasonal variation in the activity of systemic lupus erythematosus. J Rheumatol. 2012;39(7):1392–1398. doi:10.3899/jrheum.11119622660806
   PubMed Web of Science ®Google Scholar
• Merklen-Djafri C, Bessis D, Frances C, et al. Blisters and loss of epidermis in patients with lupus erythematosus: a clinicopathological study of 22 patients. Medicine (Baltimore). 2015;94(46):e2102. doi:10.1097/MD.000000000000087426579826
   PubMed Web of Science ®Google Scholar
• Perera GK, Black MM, McGibbon DH. Bullous subacute cutaneous lupus erythematosus. Clin Exp Dermatol. 2004;29(3):265–267. doi:10.1111/j.1365-2230.2004.01498.x15115507
   PubMed Web of Science ®Google Scholar
• Ryan E, Marshman G, Astill D. Toxic epidermal necrolysis-like subacute cutaneous lupus erythematosus. Australas J Dermatol. 2012;53(4):303–306. doi:10.1111/j.1440-0960.2011.00842.x23157783
   PubMed Web of Science ®Google Scholar
• Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol. 2009;10(6):365–381. doi:10.2165/11310780-000000000-0000019824738
   PubMed Web of Science ®Google Scholar
• Achtman JC, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Arthritis Res Ther. 2015;17:182. doi:10.1186/s13075-015-0706-226257198
   PubMed Web of Science ®Google Scholar
• Wenzel J, Tuting T. An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in “interface dermatitis”. J Invest Dermatol. 2008;128(10):2392–2402. doi:10.1038/jid.2008.9618418411
   PubMed Web of Science ®Google Scholar
• Ziemer M, Kardaun SH, Liss Y, Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. Br J Dermatol. 2012;166(3):575–600. doi:10.1111/j.1365-2133.2011.10705.x22014091
   PubMed Web of Science ®Google Scholar
• Crowson AN, Magro C. The cutaneous pathology of lupus erythematosus: a review. J Cutan Pathol. 2001;28(1):1–23.doi:10.1034/j.1600-0560.2001.280101.x11168747
   PubMed Web of Science ®Google Scholar
• Chhabra S, Minz RW, Saikia B. Immunofluorescence in dermatology. Indian J Dermatol Venereol Leprol. 2012;78(6):677–691. doi:10.4103/0378-6323.10235523075636
   PubMed Web of Science ®Google Scholar
• Yu J, Brandling-Bennett H, Co DO, Nocton JJ, Stevens AM, Chiu YE. Toxic epidermal necrolysis-like cutaneous lupus in pediatric patients: a case series and review. Pediatrics. 2016;137(6):e20154497. doi:10.1542/peds.2015-449727245834
   PubMed Web of Science ®Google Scholar
• Baker MG, Cresce ND, Ameri M, Martin AA, Patterson JW, Kimpel DL. Systemic lupus erythematosus presenting as Stevens-Johnson syndrome/toxic epidermal necrolysis. J Clin Rheumatol. 2014;20(3):167–171. doi:10.1097/RHU.000000000000008824662561
   PubMed Web of Science ®Google Scholar
• Mutasim DF, Adams BB. Immunofluorescence in dermatology. J Am Acad Dermatol. 2001;45(6):803–822. ( quiz 822-804). doi:10.1067/mjd.2001.11751811712024
   PubMed Web of Science ®Google Scholar
• Patsinakidis N, Gambichler T, Lahner N, Moellenhoff K, Kreuter A. Cutaneous characteristics and association with antinuclear antibodies in 402 patients with different subtypes of lupus erythematosus. J Eur Acad Dermatol Venereol. 2016;30(12):2097–2104. doi:10.1111/jdv.1376927431977
   PubMed Web of Science ®Google Scholar
• Tankunakorn J, Sawatwarakul S, Vachiramon V, Chanprapaph K. Stevens-Johnson syndrome and toxic epidermal necrolysis-like lupus erythematosus. J Clin Rheumatol. 2019;25(5):224–231. doi:10.1097/RHU.000000000000083029912772
   PubMed Web of Science ®Google Scholar
• Simsek I, Cinar M, Erdem H, Pay S, Meric C, Dinc A. Efficacy of plasmapheresis in the treatment of refractory toxic epidermal necrolysis-like acute cutaneous lupus erythematosus. Lupus. 2008;17(6):605–606. doi:10.1177/096120330808934118539717
   PubMed Web of Science ®Google Scholar
• Gaitanis G, Spyridonos P, Patmanidis K, et al. Treatment of toxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin. Dermatology. 2012;224(2):134–139. doi:10.1159/00033820222572593
   PubMed Web of Science ®Google Scholar
• Moulis G, Sommet A, Lapeyre-Mestre M, Montastruc JL. Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database. Rheumatology (Oxford). 2014;53(10):1864–1871. doi:10.1093/rheumatology/keu21424899660
   PubMed Web of Science ®Google Scholar
• Napolitano M, Giampetruzzi AR, Didona D, Papi M, Didona B. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus successfully treated with a single dose of etanercept: report of three cases. J Am Acad Dermatol. 2013;69(6):e303–e305. doi:10.1016/j.jaad.2013.07.03624238188
   PubMed Web of Science ®Google Scholar
• Paradisi A, Abeni D, Bergamo F, Ricci F, Didona D, Didona B. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol. 2014;71(2):278–283. doi:10.1016/j.jaad.2014.04.04424928706
   PubMed Web of Science ®Google Scholar
• Vital EM, Wittmann M, Edward S, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheumatol. 2015;67(6):1586–1591. doi:10.1002/art.3908525707733
   PubMed Web of Science ®Google Scholar
• Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833–1838. doi:10.1136/annrheumdis-2011-20083122550315
   PubMed Web of Science ®Google Scholar
• Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(11):1909–1916. doi:10.1136/annrheumdis-2015-20856227009916
   PubMed Web of Science ®Google Scholar
• Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(2):376–386. doi:10.1002/art.3996228130918
   PubMed Web of Science ®Google Scholar
• Werth VP, Fiorentino D, Sullivan BA, et al. Brief report: pharmacodynamics, safety, and clinical efficacy of AMG 811, a human anti-interferon-gamma antibody, in patients with discoid lupus erythematosus. Arthritis Rheumatol. 2017;69(5):1028–1034. doi:10.1002/art.4005228118537
   PubMed Web of Science ®Google Scholar
• Kubo S, Nakayamada S, Tanaka Y. Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update. Expert Rev Clin Immunol. 2019;15(7):696–700. doi:10.1080/1744666X.2019.1608821.
   Web of Science ®Google Scholar
• Shreberk-Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: A systematic review. J Am Acad Dermatol. 2017;76(4):745–753.e719. doi:10.1016/j.jaad.2016.12.00428169015
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222–231. doi:10.1016/S0140-6736(18)31363-130043749
   PubMed Web of Science ®Google Scholar
• Sebaratnam DF, Murrell DF. Bullous systemic lupus erythematosus. Dermatol Clin. 2011;29(4):649–653.doi:10.1016/j.det.2011.06.002.21925012
   PubMed Web of Science ®Google Scholar
• Pan M, Tang HD, Zhu HQ, Dong J, Gill J, Zheng J. Partial epilepsy as an initial manifestation in bullous systemic lupus erythematosus. Lupus. 2011;20(8):886–890. doi:10.1177/096120331139851121576204
   PubMed Web of Science ®Google Scholar
• Yell JA, Allen J, Wojnarowska F, Kirtschig G, Burge SM. Bullous systemic lupus erythematosus: revised criteria for diagnosis. Br J Dermatol. 1995;132(6):921–928. doi:10.1111/j.1365-2133.1995.tb16950.x7662571
   PubMed Web of Science ®Google Scholar
• Chanprapaph K, Sawatwarakul S, Vachiramon V. A 12-year retrospective review of bullous systemic lupus erythematosus in cutaneous and systemic lupus erythematosus patients. Lupus. 2017;26(12):1278–1284. doi:10.1177/096120331769971428358242
   PubMed Web of Science ®Google Scholar
• Nico MM, Lourenco SV. Multiple blisters along the lip vermilion are a clue to bullous lupus erythematosus. Acta Derm Venereol. 2012;92(4):404–405. doi:10.2340/00015555-127622293956
   PubMed Web of Science ®Google Scholar
• Vassileva S. Bullous systemic lupus erythematosus. Clin Dermatol. 2004;22(2):129–138. doi:10.1016/j.clindermatol.2003.12.02015234014
   PubMed Web of Science ®Google Scholar
• Sirka CS, Padhi T, Mohanty P, Patel DK, Parida PR, Kar CR. Bullous systemic lupus erythematosus: response to dapsone in two patients. Indian J Dermatol Venereol Leprol. 2005;71(1):54–56.doi:10.4103/0378-6323.1379516394370
   PubMedGoogle Scholar
• Chan LS, Lapiere JC, Chen M, et al. Bullous systemic lupus erythematosus with autoantibodies recognizing multiple skin basement membrane components, bullous pemphigoid antigen 1, laminin-5, laminin-6, and type VII collagen. Arch Dermatol. 1999;135(5):569–573. doi:10.1001/archderm.135.5.56910328198
   PubMedGoogle Scholar
• Barbosa WS, Rodarte CM, Guerra JG, Maciel VG, Fleury Junior LF, Costa MB. Bullous systemic lupus erythematosus: differential diagnosis with dermatitis herpetiformis. An Bras Dermatol. 2011;86(4 Suppl 1):S92–S95. doi:10.1590/s0365-0596201100070002422068782
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi:10.1002/1529-0131(199707)40:7<1267::AID-ART11>3.0.CO;2-L
   PubMed Web of Science ®Google Scholar
• Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–2686. doi:10.1002/art.3447322553077
   PubMed Web of Science ®Google Scholar
• Malcangi G, Brandozzi G, Giangiacomi M, Zampetti M, Danieli MG, Bullous SLE. response to methotrexate and relationship with disease activity. Lupus. 2003;12(1):63–66. doi:10.1191/0961203303lu241cr12587829
   PubMed Web of Science ®Google Scholar
• Duan L, Chen L, Zhong S, et al. Treatment of bullous systemic lupus erythematosus. J Immunol Res. 2015;2015:167064. doi:10.1155/2015/16706426090480
   PubMed Web of Science ®Google Scholar
• Alsanafi S, Kovarik C, Mermelstein AL, Werth VP. Rituximab in the treatment of bullous systemic lupus erythematosus. J Clin Rheumatol. 2011;17(3):142–144. doi:10.1097/RHU.0b013e318214f30c21441817
   PubMed Web of Science ®Google Scholar
• McDonagh JE, Isenberg DA. Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus. Ann Rheum Dis. 2000;59(3):230–232. doi:10.1136/ard.59.3.23010700434
   PubMed Web of Science ®Google Scholar
• Sezin T, Vorobyev A, Sadik CD, Zillikens D, Gupta Y, Ludwig RJ. Gene expression analysis reveals novel shared gene signatures and candidate molecular mechanisms between pemphigus and systemic lupus erythematosus in CD4(+) T cells. Front Immunol. 2017;8:1992. doi:10.3389/fimmu.2017.0199229387060
   PubMed Web of Science ®Google Scholar
• Kridin K, Laufer-Britva R, Kridin M, Comaneshter D, Batat E, Cohen AD. The relationship between pemphigus and systemic lupus erythematosus: a cross-sectional study, systematic review, and meta-analysis. Immunol Res. 2019;67(1):116–122. doi:10.1007/s12026-019-9065-430637663
   PubMed Web of Science ®Google Scholar
• Bilgic Temel A, Ergun E, Poot AM, et al. A rare case with prominent features of both discoid lupus erythematosus and pemphigus foliaceus. J Eur Acad Dermatol Venereol. 2019;33(1):e5–e7. doi:10.1111/jdv.1509929858874
   PubMed Web of Science ®Google Scholar
• Calebotta A, Cirocco A, Giansante E, Reyes O. Systemic lupus erythematosus and pemphigus vulgaris: association or coincidence. Lupus. 2004;13(12):951–953. doi:10.1191/0961203304lu1073cr15645751
   PubMed Web of Science ®Google Scholar
• Hidalgo-Tenorio C, Sabio-Sanchez JM, Tercedor-Sanchez J, Leon-Ruiz L, Perez-Alvarez F, Jimenez-Alonso J. Pemphigus vulgaris and systemic lupus erythematosus in a 46-y-old man. Lupus. 2001;10(11):824–826. doi:10.1177/09612033010100111211789495
   PubMed Web of Science ®Google Scholar
• Malik M, Ahmed AR. Dual diagnosis of pemphigus vulgaris and connective tissue disease. J Am Acad Dermatol. 2006;55(4):699–704. doi:10.1016/j.jaad.2006.04.05217010755
   PubMed Web of Science ®Google Scholar
• Mascaro JM Jr., Ferrando J, Sole MT, et al. Paraneoplastic pemphigus: a case of long-term survival associated with systemic lupus erythematosus and polymyositis. Dermatology. 1999;199(1):63–66. doi:10.1159/00001818210449962
   PubMed Web of Science ®Google Scholar
• Vassileva S, Drenovska K, Manuelyan K. Autoimmune blistering dermatoses as systemic diseases. Clin Dermatol. 2014;32(3):364–375. doi:10.1016/j.clindermatol.2013.11.00324767184
   PubMed Web of Science ®Google Scholar
• Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138(8):1019–1024. doi:10.1001/archderm.138..8.101912164739
   PubMedGoogle Scholar
• Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmun Rev. 2006;5(2):160–164.doi:10.1016/j.autrev.2005.10.00316431352
   PubMed Web of Science ®Google Scholar
• Vachvanichsanong P, Dissaneewate P. Childhood systemic lupus erythematosus in songklanagarind hospital: a potential unique subgroup. Clin Rheumatol. 1993;12(3):346–349.8258233
   PubMed Web of Science ®Google Scholar
• Gibson GE, McEvoy MT. Coexistence of lupus erythematosus and porphyria cutanea tarda in fifteen patients. J Am Acad Dermatol. 1998;38(4):569–573. doi:10.1016/s0190-9622(98)70119-79555796
   PubMed Web of Science ®Google Scholar
• Peitsch WK, Lorentz K, Goebeler M, Goerdt S. Subacute cutaneous lupus erythematosus with bullae associated with porphyria cutanea tarda. J Dtsch Dermatol Ges. 2007;5(3):220–222. doi:10.1111/j.1610-0387.2007.06201.x17338797
   PubMedGoogle Scholar